** SYBD Forms New Corp w/ Nitric Oxide Solutions **
Company Press Release
Synthetic Blood International Inc. Announces Agreement with Nitric Oxide Solutions L.L.C.
KETTERING, Ohio--(BUSINESS WIRE)--May 17, 1999--Synthetic Blood International Inc.(OTCBB:SYBD - news) announced today that it will form a new corporation with Nitric Oxide Solutions, L.L.C. (NOS) for the purpose of acquiring and developing proprietary therapeutic nitric oxide delivery technology.
NOS, a Texas company established in 1997, has developed patented technology for systemic and topical nitric oxide delivery based in part on the use of perfluorocarbon emulsions.
Nitric oxide has recently been discovered to function as a vasodilator and neurotransmitter, and is a critical part of the control mechanism of many biological functions. The anti-impotence drug Viagra(TM) works by stimulating local production of nitric oxide. Nitric oxide has the potential to treat an array of clinical conditions, including artherosclerosis, high blood pressure, respiratory distress, burn wounds, ulcers and hair loss.
"SYBD is very fortunate to be able to acquire this exciting drug delivery technology,'' said Robert Nicora, SYBD president. ''The market potential for nitric oxide is enormous and we look forward to working with NOS in the development of selected therapeutic applications."
SYBD is currently developing Oxycyte(TM), a perfluorocarbon-based blood substitute, Fluorovent(TM), a perfluorocarbon liquid ventilation product, and an implantable glucose biosensor for continuous monitoring of blood glucose levels in diabetics.
Synthetic Blood International is located in Kettering, Ohio, with West Coast offices and laboratories in Newport Beach, Calif. The company's stock is traded on the OTC Electronic Bulletin Board, symbol SYBD. The company's Web site is http://www/sybd.com and e-mail address is sybd@siscom.net.
Contact:
Synthetic Blood International Inc.
Joan Mahan, 800/809-6054
|
